Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game

Fierce Biotech looks at how Basel is building on its long-standing pharma foundations—anchored by Roche and Novartis—to grow a broader biotech ecosystem. Local leaders describe a city that’s increasingly “all-in” on life sciences, supported by the University of Basel, a business-friendly regional approach, and the appeal of living and working there.

A key symbol of that shift is the Basel Innovation Hub, opened in 2022, which has attracted a mix of large-company R&D footprints and emerging biotechs. The article also highlights Basel’s practical talent advantage: its location at the Swiss-French-German border expands the hiring pool, and strong transport links make commuting (including from Zurich) part of the region’s working reality.

On the funding side, the piece points to a recent rise in Swiss biotech financing and spotlights Basel-based companies such as Alentis Therapeutics and SixPeaks Bio as examples of scale being built locally. Several voices suggest Basel is on an upward trajectory—but that raising its international profile may require Switzerland to communicate its strengths more assertively.

CTA
Read the full article on the original source (Fierce Biotech).